Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor

Clinical Infectious Diseases

Volumn 62, Issue 11, 2016, Pages 1329-1335

  Chen, Wilbur H ^a   Cohen, Mitchell B ^b   Kirkpatrick, Beth D ^c   Brady, Rebecca C ^b   Galloway, David ^b   Gurwith, Marc ^d   Hall, Robert H ^e   Kessler, Robert A ^a   Lock, Michael ^d   Haney, Douglas ^d   Lyon, Caroline E ^c   Pasetti, Marcela F ^a   Simon, Jakub K ^d   Szabo, Flora ^b   Tennant, Sharon ^a   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d PaxVax Inc   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

challenge; cholera; efficacy; vaccine; volunteer

Indexed keywords

CHOLERA VACCINE; PLACEBO; BACTERIUM ANTIBODY;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHENIA; CHOLERA; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALAISE; MALE; NAUSEA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE DRUG DOSE; VIBRIO CHOLERAE O1; VOMITING; ADOLESCENT; BLOOD; IMMUNOLOGY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA VACCINES; FEMALE; HUMANS; MALE; MIDDLE AGED; VIBRIO CHOLERAE O1; YOUNG ADULT;

EID: 84971506957     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw145     Document Type: Article

References (40)

1. Levine MM, Kaper JB. Live oral cholera vaccine: from principle to product. Bull Inst Pasteur 1995; 93:243-53.
2. Calain P, Chaine JP, Johnson E, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 2004; 22:2444-51.
3. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988; 2:467-70.
4. Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol Lett 1993; 111:15-21.
5. Kaper JB, Levine MM. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines. Res Microbiol 1990; 141:901-6.
6. Chen WH, Greenberg RN, Pasetti MF, et al. Safety and immunogenicity of singledose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin Vaccine Immunol 2014; 21:66-73.
7. Chaudhuri A, De S. Cholera and blood-groups. Lancet 1977; 2:404.
8. Barua D, Paguio AS. ABO blood groups and cholera. Ann Hum Biol 1977; 4:489-92.
9. Levine MM, Nalin DR, Rennels MB, et al. Genetic susceptibility to cholera. Ann Hum Biol 1979; 6:369-74.
10. Sack DA, Tacket CO, Cohen MB, et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun 1998; 66:1968-72.
11. Rennels MB, Levine MM, Daya V, Angle P, Young C. Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J Infect Dis 1980; 142:328-31.
12. Benenson AS, Saad A, Mosley WH. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull World Health Organ 1968; 38:277-85.
13. Clements ML, Levine MM, Young CR, et al. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis 1982; 145:465-73.
14. Farrington CP, Gay NJ. Interval-censored survival data with informative examination times: parametric models and approximate inference. Stat Med 1999; 18:1235-48.
15. Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992; 166:837-41.
16. Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebocontrolled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun 1999; 67:6341-5.
17. Losonsky GA, Yunyongying J, Lim V, et al. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun 1996; 64:10-5.
18. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. Duration of infection-derived immunity to cholera. J Infect Dis 1981; 143:818-20.
19. Saha D, LaRocque RC, Khan AI, et al. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 2004; 189:2318-22.
20. Mukhopadhyay AK, Takeda Y, Balakrish Nair G. Cholera outbreaks in the El Tor biotype era and the impact of the new El Tor variants. Curr Top Microbiol Immunol 2014; 379:17-47.
21. Mutreja A, Kim DW, Thomson NR, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature 2011; 477:462-5.
22. Nair GB, Qadri F, Holmgren J, et al. Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. J Clin Microbiol 2006; 44:4211-3.
23. Morita M, Ohnishi M, Arakawa E, et al. Emergence and genetic diversity of El Tor Vibrio cholerae O1 that possess classical biotype ctxB among travel-Associated cases of cholera in Japan. J Med Microbiol 2010; 59:708-12.
24. Son MS, Megli CJ, Kovacikova G, Qadri F, Taylor RK. Characterization of Vibrio cholerae O1 El Tor biotype variant clinical isolates from Bangladesh and Haiti, including a molecular genetic analysis of virulence genes. J Clin Microbiol 2011; 49:3739-49.
25. Siddique AK, Nair GB, Alam M, et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 2010; 138:347-52.
26. Bart KJ, Huq Z, Khan M, Mosley WH. Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis 1970; 121(suppl 121):17
27. Pasetti MF, Levine MM. Insights from natural infection-derived immunity to cholera instruct vaccine efforts. Clin Vaccine Immunol 2012; 19:1707-11.
28. Gotuzzo E, Butron B, Seas C, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993; 61:3994-7.
29. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010; 8:129.
30. Suharyono , Simanjuntak C, Witham N, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992; 340:689-94.
31. Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18:2399-410.
32. Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005; 366:44-9.
33. Longini Jr. I.M., Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med 2007; 4:e336.
34. Sur D, Lopez AL, Kanungo S, et al. Efficacy and safety of a modified killed-wholecell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1694-702.
35. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335-44.
36. Khan MI, Soofi SB, Ochiai RL, et al. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 2012; 30:5389-95.
37. Cholera situation in the Americas. An update. Epidemiol Bull 1991; 12:1-4.
38. Newton AE, Heiman KE, Schmitz A, et al. Cholera in United States associated with epidemic in Hispaniola. Emerg Infect Dis 2011; 17:2166-8.
39. Mahon BE, Mintz ED, Greene KD, Wells JG, Tauxe RV. Reported cholera in the United States, 1992-1994: a reflection of global changes in cholera epidemiology. JAMA 1996; 276:307-12.
40. Steinberg EB, Greene KD, Bopp CA, Cameron DN, Wells JG, Mintz ED. Cholera in the United States, 1995-2000: trends at the end of the twentieth century. J Infect Dis 2001; 184:799-802.